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Abstract  
The synthesis of all 13 mitochondrial DNA (mtDNA)-encoded protein subunits of the human 
oxidative phosphorylation (OXPHOS) system is carried out by mitochondrial ribosomes 
(mitoribosomes). Defects in the stability of mitoribosomal proteins or mitoribosome assembly impair 
mitochondrial protein translation, causing combined OXPHOS enzyme deficiency and clinical 
disease. Here we report four autosomal recessive pathogenic mutations in the gene encoding the small 
mitoribosomal subunit protein, MRPS34, in six subjects from four unrelated families with Leigh 
syndrome and combined OXPHOS defects. Whole exome sequencing was used to independently 
identify all variants. Two splice-site mutations were identified, including homozygous c.321+1G>T in 
a subject of Italian ancestry and homozygous c.322-10G>A in affected sibling pairs from two 
unrelated families of Puerto Rican descent. In addition, compound heterozygous MRPS34 mutations 
were identified in a proband of French ancestry; a missense (c.37G>A, p.Glu13Lys) and a nonsense 
variant (c.94C>T, p.Gln32*). We demonstrated that these mutations reduce MRPS34 protein levels 
and the synthesis of OXPHOS subunits encoded by mtDNA. Examination of the mitoribosome profile 
and quantitative proteomics showed that the mitochondrial translation defect was caused by 
destabilization of the small mitoribosomal subunit and impaired monosome assembly. Lentiviral-
mediated expression of wild-type MRPS34 rescued the defect in mitochondrial translation observed in 
skin fibroblasts from affected subjects, confirming the pathogenicity of MRPS34 mutations. Our data 
establish that MRPS34 is required for normal function of the mitoribosome in humans, and 
furthermore demonstrate the power of quantitative proteomic analysis to identify signatures of defects 
in specific cellular pathways in fibroblasts from subjects with inherited disease. 
 
Main Text 
Introduction 
The oxidative phosphorylation (OXPHOS) system generates the majority of cellular energy required 
by the body. Mitochondrial DNA (mtDNA) encodes 13 protein subunits of the OXPHOS system via 
11 mRNAs, two of which are bicistronic (MT-ATP8/MT-ATP6 and MT-ND4L/MT-ND4), as well as 
22 transfer RNAs (mt-tRNA) required for translation and 2 ribosomal RNAs (mt-rRNA) necessary for 
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the assembly of mitochondrial ribosomes (mitoribosomes). Nuclear genes encode all of the other 
proteins required for mitochondrial translation, including mitoribosomal proteins, tRNA- and rRNA-
modifying enzymes and additional factors that mediate mitoribosome biogenesis and translation 
initiation, elongation, and termination.1  
 
Mammalian mitoribosomes contain two subunits; a small (28S) subunit that decodes mRNA and 
mediates tRNA delivery of required amino acids, and a large (39S) subunit that catalyzes the 
formation of peptide bonds between the amino acids.2,3 In humans, 30 mitochondrial ribosomal small 
subunit proteins (MRPSs) assemble with the 12S mt-rRNA to form the small 28S subunit, while 50 
mitochondrial ribosomal large subunit proteins (MRPLs) assemble with the 16S mt-rRNA and mt-
tRNAVal to form the large 39S subunit.4-6  
 
Molecular defects that impair different components of the mitochondrial translation machinery can 
cause combined OXPHOS deficiency.7 Specifically, 7 of the 80 genes encoding mitochondrial 
ribosomal proteins have had pathogenic mutations reported, including autosomal recessive mutations 
in MRPS7 (MIM: 611974),8 MRPS16 (MIM: 609204),9 MRPS22 (MIM: 605810),10 MRPS23 (MIM: 
611985),11 MRPL3 (MIM: 607118),12 MRPL12 (MIM: 602375),13 and MRPL44 (MIM: 611849).14 
Disorders caused by mutations in mitoribosomal proteins are clinically heterogeneous and multi-
systemic, with common features including neurodevelopmental disabilities, brain abnormalities, liver 
disease, kidney disease, cardiomyopathy, and lactic acidosis.11,15 They generally lead to death in 
infancy or early childhood,15 although survival into teenage years and adulthood has been 
reported.8,14,16 The small number of mitoribosomal genes known to underlie OXPHOS diseases is 
surprising, since nearly two-thirds of mitoribosomal genes are essential for OXPHOS based on a high-
throughput knock-out death screen in cell models.17 
 
Here, we report four pathogenic recessive mutations in a small mitoribosome subunit gene not 
previously associated with human disease, MRPS34, that were identified in six individuals from four 
families with combined OXPHOS defects and Leigh syndrome or Leigh-like disease (MIM: 256000). 
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MRPS34, which lies within the foot of the small 28S mitoribosome subunit, is one of 15 mammalian 
mitochondria-specific MRPSs not found in the ancestral bacterial ribosome.5 We previously showed 
that mice with a homozygous Mrps34 missense mutation that caused reduced MRPS34 protein 
stability developed cardiac hypertrophy and pronounced liver dysfunction due to impaired 
mitoribosome assembly.18 We now demonstrate that human MRPS34 mutations cause Leigh or Leigh-
like syndrome by destabilizing the small mitoribosomal subunit and impairing mitochondrial protein 
translation.  
 
Subjects and Methods 
Samples from probands and family members were obtained after receiving informed consent for 
diagnostic or research investigations, and associated studies were performed in accordance with the 
Declaration of Helsinki and approved by the respective human research institutional review board 
responsible for each research site. 
 
Clinical Information 
A summary of features in the six affected subjects from four unrelated families is shown in Table 1, 
with detailed descriptions provided in the Supplemental material (Case Reports and Table S1). Most 
subjects had normal neonatal periods, with subsequent onset of developmental delay in all patients by 
6 months of age that typically evolved to neurodevelopmental regression. Subjects 1 and 4 had failure 
to thrive in the first few months of life, and episodic metabolic acidosis with respiratory distress, with 
death during an episode between 8 to 9 months of age. They had progressive clinical courses with 
brain MRI and/or neuropathology analysis showing lesions in the basal ganglia, brainstem and/or 
midbrain that were diagnostic of the progressive neurodegenerative disorder Leigh syndrome (Figure 
S1 for subject 4 MRI).19 Similar but milder clinical courses typical of Leigh or Leigh-like syndrome 
have been seen in subjects 2a, 2b, 3a and 3b, with all still alive at ages ranging from 2 to 17 years. 
The subject with Leigh-like syndrome had neuroradiological imaging that did not fulfil stringent 
diagnostic criteria for Leigh syndrome.19 The three older subjects have developed dystonic and/or 
choreoathetoid movements, with wheelchair dependence. Four of the subjects had OXPHOS 
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enzymology performed in skeletal muscle, liver and/or skin fibroblast cell lines, which showed 
deficiency of one or more OXPHOS complexes (Tables 1 and S2). 
 
Enzyme assays 
Spectrophotometric enzyme assays assessing mitochondrial OXPHOS enzyme and citrate synthase 
activities in cultured fibroblasts, skeletal muscle and liver biopsy were performed as described 
previously for subjects 1 and 4.20,21 For subject 2a, clinical skeletal muscle OXPHOS enzymology 
testing was performed at 19 months at All Children’s Hospital (St. Petersburg, Florida, USA) and at 
12 years at MNG Laboratories (Atlanta, Georgia, USA). Enzyme studies for subject 3a were 
performed at Baylor Medical Genetics Laboratory. Dipstick assays to measure complexes I and IV 
activity in lentiviral rescue studies were performed on 15 μg of fibroblast lysates as described 
previously.22 
 
Whole exome sequencing 
Whole exome sequencing (WES) of subject 1 was performed at the Broad Institute using Illumina 
Capture Exome technology (version 1) supplemented with additional baits to ensure capture of 
mtDNA. Data were mapped to NCBI hg19/GRCh37 human genome reference sequence using 
BWA,23 and then analyzed using GATK Best Practices recommendations,24 HaplotypeCaller,25,26 
Variant Effect Predictor,27 and Seqr. Analysis of mtDNA was performed as described previously.28 
 
Clinical WES testing was performed for subjects 2a, 2b, 3a and their parents as described.19 DNA 
libraries were generated using the SureSelect Human All Exon V4 or Clinical Research Exome kit 
(Agilent Technologies, Santa Clara, California, USA). Data were mapped to the NCBI hg19/GRCh37 
human genome reference sequence and analyzed using GeneDx’s XomeAnalyzer. Variants identified 
by WES were evaluated and classified according to published guidelines.20 The homozygous variant 
identified in subject 3a was confirmed as homozygous in the similarly affected sibling subject 3b by 
Sanger sequencing. Whole mitochondrial genome sequencing analysis in blood was performed for 
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subjects 2a and 3a; mtDNA sequence was assembled and analyzed relative to the revised Cambridge 
Reference Sequence (rCRS) and MITOMAP database as previously described.29  
 
Prior to clinical WES, blood DNA from subjects 2a and 2b were also processed for WES in the Mount 
Sinai Genomics Core Facility using SureSelect V5 libraries (Agilent). Alignment and variant calling 
using an in-house GATK-based pipeline, plus variant filtering using Ingenuity Variant Analysis 
(Qiagen), were performed as described previously.30  
 
WES for subject 4 utilized Agilent SureSelect Human All Exon V libraries. Reads were mapped to the 
NCBI hg19/GRCh37 human genome reference sequence and variant calling utilized GATK, 
SAMtools and Picard Tools. Single nucleotide variants were called with GATK Unified Genotyper, 
whereas indel calls were made with the GATK IndelGenotyper_v2. Variants were annotated and 
filtered using in-house software PolyWeb as described elsewhere.31  
 
RNA and DNA Analyses 
DNA was extracted from primary skin fibroblasts as described previously.22 For cDNA studies of 
subject 1, cultured fibroblasts were grown with and without cycloheximide treatment, as described 
previously.32 For cDNA studies of subjects from families 2 and 3, cultured fibroblasts or Epstein-Barr 
Virus transformed lymphoblasts were grown without cycloheximide treatment. Total RNA was 
extracted using the miRNeasy Mini kit (Qiagen) as per manufacturer’s protocol and as described 
previously.32 Synthesis of cDNA was performed using the SuperScript IV First-Strand Synthesis 
System (ThermoFisher Scientific) as per manufacturer’s protocol and as described previously.32 To 
examine the effect of the c.321+1G>T and the c.322-10G>A mutations on mRNA splicing, PCR 
primers were designed to amplify exons 1-3 of MRPS34 from cDNA (using either pair 1 [forward 
primer 5’CGGGAGCAACTGAACAGG, reverse primer 5’TGCGTATCCTCTGCACATTC] or pair 
2 [forward primer 5’AGCTCTACGCGGTGGACTAC, reverse primer 5’ 
GATCCAGGCAGAGAGAGCAC] respectively). PCR products amplified from the MRPS34 
transcript containing the c.322-10G>A mutation were cloned into the pCRTM4-TOPO TA vector 
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using the TOPO TA cloning kit (ThermoFisher Scientific). The vector was transformed into TOP10 
competent cells (Invitrogen), and individual colonies were examined and sequenced. 
 
Lentiviral Transduction 
For subject 1, lentiviral transduction of fibroblasts was performed as described previously.22 For 
subject 4, fibroblasts were transduced with lentiviral particles expressing RFP or wild-type MRPS34 
using the p.Lenti7.3 (ThermoFisher Scientific) for 12 hours and then incubated for an additional 20 
days until the cells were harvested.   
 
SDS-PAGE and Blue Native Gel Electrophoresis (BN-PAGE) 
Protein was extracted from cultured fibroblasts, lymphoblasts, and liver biopsies, and 10-30 μg of 
each protein lysate was analyzed by SDS-PAGE as described previously.32,33 BN-PAGE was 
performed on 100 μg of fibroblast mitochondria lysate in 1% Triton X-100 as described 
previously,34,35 or on 15 μg fibroblast mitoplast extract in 1% dodecyl maltoside as described 
previously.36 
 
Immunoblotting 
Protein lysates analyzed by SDS-PAGE were probed with primary antibodies against MRPS34 
(Sigma-Aldrich), MRPL37 (Proteintech or Sigma-Aldrich), MRPL11 (Proteintech), MRPS2 (Abcam), 
MRPS5 (Abcam), MRPS16 (Proteintech), MRPS18B (Proteintech), MRPS35 (Proteintech), GAPDH 
(Cell Signalling), NDUFS3 (Abcam), complex II 70 kDa subunit (Molecular Probes), COXI (Abcam), 
VDAC1 (MitoSciences or Abcam), Beta-Actin (Abcam), Citrate Synthase (GeneTex,) and Total 
OXPHOS Human WB Antibody Cocktail (consisting of five antibodies ATP5A, UQCRC2, SDHB, 
COXII, and NDUFB8; Abcam). Isolated mitochondria and mitoplasts analyzed by BN-PAGE were 
probed with Total OXPHOS Rodent WB Antibody Cocktail (consisting of five antibodies ATP5A, 
UQCRC2, COXI, SDHB, and NDUFB8; Abcam) or with primary antibodies against NDUFA13, 
SDHA, UQCRC2, COXIV, ATP5A (Abcam) respectively. Blots were incubated with anti-mouse or 
anti-rabbit IgG secondary antibodies (VWR International) and developed with Clarity Western ECL 
 9 
 
Substrate (Bio-Rad Laboratories), or with IRDye 800CW/680LT Goat Anti-Rabbit or Anti-Mouse 
IgG (Li- Cor) secondary antibodies and visualized using an Odyssey Infrared Imaging System (Li-
Cor). Relative band intensities were quantitated using Image J software, where protein levels were 
normalized to VDAC1. 
 
Sucrose Gradient Subfractionation 
Fibroblast mitochondria were prepared from 8 x 15cm2 dishes as described previously,37 and the 
isolated mitochondria were lysed with 2% digitonin in 260 mM Sucrose, 10 mM Tris HCl, pH 7.5, 
100mM KCl and 20 mM MgCl2 in the presence of 1x Complete EDTA-free Protease inhibitor 
cocktail for 20 min as previously described.38 The mitochondrial lysate was centrifuged for 45 min at 
9200 g at 4°C, the clarified lysate was loaded onto a continuous 10-30% sucrose gradient (in 10 mM 
Tris-HCl, pH 7.4, 100 mM KCl, 20 mM MgCl2 in the presence of protease inhibitors) and centrifuged 
at 71,000 g in an Optima Beckman Coulter preparative ultracentrifuge for 15 hours. Fractions were 
collected and precipitated with 0.02% sodium deoxycholate and 12% trichloroacetic acid (final 
concentration), washed twice with acetone, and the entire precipitate was resolved by SDS-PAGE. 
Protein markers of the mitochondrial ribosomal subunits were detected by immunoblotting, as 
described above. 
 
Mitochondrial protein synthesis assay 
Mitochondrial protein synthesis was analyzed in fibroblasts using previously described methods.37,39-41 
 
Quantitative Proteomics 
Mass-spectrometry on primary fibroblast material was performed label-free, using sample preparation 
methodology previously described with modifications.42 Fibroblasts from three separate controls and 
two subcultures of subject 1 cultured as above were solubilized in 1% w/v sodium deoxycholate, 100 
mM Tris-HCl (pH 8.1) prior to incubation at 99˚C for 10 minutes with vortexing. Samples were 
further incubated for 10 minutes at 60˚C in a sonicator waterbath, followed by the addition of 5 mM 
Tris(2-carboxyethy)phosphine (TCEP), 20 mM chloroacetamide and incubation for 5 min at 99˚C 
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with vortexing. Denatured and alkylated proteins were digested with trypsin overnight at 37˚C. 
Detergent was removed by extraction into ethyl acetate in the presence of 2 % formic acid (FA), 
followed by concentration of the aqueous phase through vacuum centrifugation. Peptides 
reconstituted in 0.5 % FA were loaded onto small cation exchange (Empore Cation Exchange-SR, 
Supelco Analytical) stage-tips made in-house.43 Tips were washed with 20 % acetonitrile (ACN), 0.5 
% FA and eluted over five fractions of increasing amounts (45-300 mM) freshly prepared ammonium 
acetate, 20 % ACN, 0.5 % FA, followed by a final elution of 5 % ammonium hydroxide, 80 % ACN. 
Fractions were concentrated by vacuum centrifugation and desalted on SDB-XC poly(styrene-divinyl-
benzene; Supelco Analytical) stage-tips as previously described.40,43 Peptides were reconstituted in 
0.1% trifluoroacetic acid (TFA), 2% ACN and analyzed by online nano-HPLC/electrospray 
ionization-MS/MS on a Q Exactive Plus connected to an Ultimate 3000 HPLC (Thermo-Fisher 
Scientific). Peptides were loaded onto a trap column (Acclaim C18 PepMap nano Trap x 2 cm, 100 μm 
I.D, 5 μm particle size and 300 Å pore size; ThermoFisher Scientific) at 15 μL/min for 3 min before 
switching the pre-column in line with the analytical column (Acclaim RSLC C18 PepMap Acclaim 
RSLC nanocolumn 75 μm x 50 cm, PepMap100 C18, 3 μm particle size 100 Å pore size; 
ThermoFisher Scientific). The separation of peptides was performed at 250 nL/min using a non-linear 
ACN gradient of buffer A (0.1% FA, 2% ACN) and buffer B (0.1% FA, 80% ACN), starting at 2.5% 
buffer B to 35.4% followed by ramp to 99% over 120 minutes. Data were collected in positive mode 
using Data Dependent Acquisition using m/z 375 - 1800 as MS scan range, HCD for MS/MS of the 
12 most intense ions with z ≥ 2. Other instrument parameters were: MS1 scan at 70,000 resolution (at 
200 m/z), MS maximum injection time 50 ms, AGC target 3E6, Normalized collision energy was at 
27% energy, Isolation window of 1.8 Da, MS/MS resolution 17,500, MS/MS AGC target of 1E5, 
MS/MS maximum injection time 100 ms, minimum intensity was set at 1E3 and dynamic exclusion 
was set to 15 sec.  
 
Raw files were analyzed using the MaxQuant platform44 version 1.5.5.1 searching against the Uniprot 
human database containing reviewed, canonical and isoform variants in FASTA format (June 2016) 
and a database containing common contaminants. Default search parameters for a label-free (LFQ) 
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experiment were used. Briefly, multiplicity was set to 1 (unlabeled), “LFQ”, “Re-quantify” and 
“Match between runs” were enabled with default settings. Unique and razor peptides were used for 
quantification, using a minimum ratio count of 2. Using the Perseus platform version 1.5.5.3,45 
proteins identified using < 2 unique peptides were excluded, as were identifications marked “Only 
identified by site”, “Reverse”, and “Potential Contaminant”. Mitochondrial proteins were defined 
through matching of gene names and Ensembl gene IDs to the Mitocarta2.0 dataset.46 LFQ Intensity 
values were Log2 transformed, and mean and standard deviations were calculated for each 
experimental group, consisting of either 3 control fibroblast biological replicates or 2 subject 
fibroblast technical replicates. Values from a group with a standard deviation > 0.3 were invalidated 
by conversion to “NaN” and rows were filtered to contain at least 2 valid values in both experimental 
groups. A two-tailed ratio paired t-test was performed on the linearised Log2 LFQ Intensity Mean 
values for controls and subject 1. The D'Agostino and Pearson normality test was used to confirm that 
the log of the ratios followed a Gaussian distribution. The Bonferroni correction was used to 
determine the p-value threshold for significance.  
 
Mapping of subunit levels to complex I (PDB: 5LDW) was performed as previously described.42,47 
For mitoribosome subunit mapping the human mitoribosome structure (PDB: 3J9M) was used.48 For 
complexes III and IV homologous human subunits were mapped to the bovine structures PDB: 1BGY 
and PDB: 5B1A respectively,49,50 whereas for complex II homologous human subunits were mapped 
to those found in the porcine structure (PDB: 1ZOY).51  
 
Results  
Whole exome sequencing identified MRPS34 autosomal recessive mutations in individuals with 
Leigh (-like) syndrome 
We analyzed six subjects from four families with Leigh or Leigh-like syndrome and OXPHOS defects 
(Figure 1A and Table 1). WES studies identified homozygous or compound heterozygous pathogenic 
variants in MRPS34 (GenBank: NM_023936.1) in all subjects, which were confirmed by Sanger 
sequencing (Figure 1B). A homozygous essential splice site mutation, c.321+1G>T, was identified in 
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subject 1, an Australian child with consanguineous parents of Italian ancestry. This variant is 
predicted to cause abnormal splicing by abolishing the donor splice site of exon 1. The MRPS34 
c.321+1G>T variant is absent from dbSNP and the Genome Aggregation Database (gnomAD) 
Browser.52,53 A homozygous extended splice site mutation, c.322-10G>A, was identified in subjects 
2a, 2b, 3a and 3b of Puerto Rican ethnicity; these subjects were ascertained with assistance from the 
GeneMatcher tool.54 This variant is predicted to abolish the acceptor splice site and create a new 
cryptic splice acceptor site within intron 1, causing abnormal gene splicing. The MRPS34 c.322-
10G>A variant is reported in dbSNP (dbSNP: rs563189672), and 2 heterozygous individuals (both of 
Latino ethnicity) were reported in the gnomAD Browser (2 of 236,804 alleles examined, no 
homozygotes observed). Principal component analysis of available WES data revealed that 
individuals from families 2 and 3 all fall in the Admixed American (AMR) group, and their close 
clustering indicated they come from a very similar population (Table S3 and Figure S2). Kinship 
analysis showed that there is no consanguinity at the level of 2nd cousins or closer between the parents 
either within or across families 2 and 3 (Table S4). Analysis of the variants in the MRPS34 genomic 
region using WES data from families 2 and 3 showed a shared haplotype of ~590kb in size between 
chr16:1,306,986-1,894,912 (Table S5), implying that the c.322-10G>A mutation is a founder 
mutation.  
 
Compound heterozygous MRPS34 mutations were identified in subject 4, a c.37G>A (p.Glu13Lys) 
missense variant and a c.94C>T (p.Gln32*) nonsense variant. The c.37G>A (p.Glu13Lys) variant is 
absent from dbSNP and the gnomAD Browser. Protein sequence alignment of human MRPS34 with 
its homologs in nine other vertebrate species indicated that the p.Glu13 residue is highly conserved 
(Figure 1C). The MRPS34 c.37G>A (p.Glu13Lys) missense variant is predicted as ‘Damaging’ by 
SIFT (score 0.02), ‘Disease Causing’ by MutationTaster (score 1.0), ‘Probably Damaging’ by 
PolyPhen-2 (score 0.97) and likely to interfere with function by AlignGVD (Class C55, second 
highest class of 7). The MRPS34 c.94C>T (p.Gln32*) variant is reported in dbSNP (dbSNP: 
rs763672163), and 39 heterozygous individuals were reported in the gnomAD Browser (39 of 82,878 
alleles examined, no homozygotes observed). Investigation of family members with DNA available 
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confirmed that all variants segregated with disease (Figures 1A and 1B). The MRPS34 variants not 
reported in dbSNP have been submitted to ClinVar (see Accession Numbers). 
 
The MRPS34 c.321+1G>T and c.322-10G>A mutations cause abnormal mRNA splicing 
The c.321+1G>T variant (subject 1) lies within the highly conserved donor splice site of exon 1, 
while the c.322-10G>A variant (families 2 and 3) is situated within the extended acceptor site of exon 
2. To examine the effect of these variants on MRPS34 splicing, PCR was performed on cDNA 
synthesized from fibroblast or lymphoblast RNA extracted from controls and subjects 1 and 2a. For 
the c.321+1G>T variant, gel electrophoresis of PCR products containing exons 1-3 of MRPS34 
revealed an amplicon in subject 1 that was smaller than that in control (Figure 2A). Sequencing 
determined that this amplicon lacked the last 24 bases of exon 1, indicating the use of an upstream 
donor splice site within exon 1 (Figure 2B). The c.321+1G>T variant therefore produces a shortened, 
stable transcript that results in an in-frame deletion of 8 amino acids, p.Val100_Gln107del (Figure 
2C). Protein sequence alignment of human MRPS34 with its homologs in nine other vertebrate 
species indicated that the missing 8 amino acids are highly conserved (Figure 2D).  
 
To determine the effect of the c.322-10G>A variant on splicing, MRPS34 PCR products amplified 
from fibroblast and lymphoblast cDNA were cloned and sequenced. Two abnormally spliced MRPS34 
transcripts resulting in frameshifts and premature truncations were detected in subject 2a; an amplicon 
with 8 nucleotides inserted prior to exon 2 due to the utilization of a cryptic intronic acceptor site 
(p.Asn108Leufs*12), which represented 80% or 68% of total PCR products analyzed in fibroblasts 
and lymphoblasts respectively, and an amplicon which skipped exon 2 (p.Asn108Glyfs*50) observed 
in 10% or 18% of total PCR products analyzed in fibroblasts or lymphoblasts respectively. The 
remaining analyzed PCR products were wild-type (10% or 15% in fibroblasts and lymphoblasts 
respectively) (Figure 2C). Quantitative RT-PCR analysis of fibroblast cDNA revealed a ~75% 
reduction in MRPS34 transcript level in cells from subject 3a relative to control (Figure S3). 
Collectively, these results confirm that the c.321+1G>T and c.322-10G>A variants cause impaired 
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splicing of the MRPS34 transcript. The latter variant allows some wild-type mRNA to be made, 
implying it is a hypomorphic allele. 
 
MRPS34 protein levels are reduced in individuals with MRPS34 recessive mutations 
To investigate the effect of the mutations on MRPS34 protein levels, immunoblotting was performed 
on available tissue and cells from controls and subjects 1, 2a, 2b and 4. Immunoblotting of fibroblasts 
and liver tissue confirmed the absence of wild-type MRPS34 protein in subject 1 (Figure 2E), and 
longer exposure of the immunoblots revealed two bands in subject 1 that were faint but detectable, 
one of which may represent the mutant MRPS34 protein (p.Val100_Gln107del). These results suggest 
that the mutant MRPS34 protein is likely degraded in subject 1. In cells from subjects 2a, 2b and 4, a 
substantial decrease in MRPS34 protein levels was identified relative to controls (Figures 2F and 2G). 
The residual protein in subjects 2a and 2b with the homozygous c.322-10G>A mutation likely reflects 
the presence of residual wild-type transcript. These findings establish that all the MRPS34 mutations 
identified in the affected subjects result in decreased MRPS34 protein levels.  
 
Individuals with MRPS34 mutations have combined OXPHOS deficiency associated with 
reduced mitochondrial translation 
Spectrophotometric enzyme assays performed on liver, skeletal muscle and/or fibroblasts identified a 
combined OXPHOS deficiency in subjects 1, 2a, and 3a, and isolated complex IV deficiency in 
subject 4 (Table S2). Immunoblotting of cell lysates from controls and subjects 1, 2a, 2b, and 4 
revealed decreased levels of OXPHOS complex I and IV subunits in affected subjects relative to 
controls (Figures 3A - 3C). This was associated with a decrease in the steady-state levels of assembled 
complexes I and IV in fibroblasts from subject 1, as demonstrated by BN-PAGE (Figure 3D). BN-
PAGE also showed a decrease in assembled complex I in subject 4, but complex IV assembly was not 
clearly decreased below controls (Figure 3E). Given that MRPS34 is a component of the 
mitoribosome, we sought to determine whether the combined OXPHOS deficiency was due to 
reduced mitochondrial translation. Examination of mitochondrial de novo protein synthesis in 
fibroblasts from subjects 1 and 4 by 35S-methionine radiolabeling revealed an overall decrease in 
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protein synthesis of mtDNA-encoded OXPHOS subunits in the affected subjects relative to controls 
(Figures 3F, 3G and S4). BN-PAGE analysis of pulse-chase 35S-methionine labeled mitochondrial 
lysates suggested that subject 1 cells had a reduced rate of complex IV formation relative to control 
(Figure 3H). These findings demonstrate that MRPS34 is required for efficient mitochondrial 
translation in humans.   
 
MRPS34 mutation reduces mitochondrial translation by destabilizing the small mitoribosomal 
subunit   
We have previously established that decreased protein levels of MRPS34 in mice with a Mrps34 
missense mutation destabilized the small mitoribosomal subunit.18 To determine the effect of MRPS34 
mutation on the stability of the small mitoribosomal subunit in affected human subjects, we 
investigated the steady state levels of other small mitoribosomal subunit proteins in fibroblast lysates 
from controls and subjects 1 and 4 by immunoblotting. The steady state abundance of various small 
mitoribosomal subunit proteins was reduced in subjects 1 and 4 relative to controls (Figures 4A and 
4B). Interestingly, the abundance of large mitoribosomal subunit proteins was not affected by the 
MRPS34 mutation (Figures 4A and 4B). To investigate how the decrease in small mitoribosomal 
subunit proteins affects the mitoribosome, we analyzed the profile of the large and small 
mitoribosomal subunits, as well as the monosome and polysome, in fibroblast mitochondrial lysates 
using sucrose gradients. Immunoblotting of the sucrose gradient fractions showed a decrease in 
actively translating mitochondrial ribosomes in subject 1 relative to control (Figure 4C). In 
mitochondria isolated from subject 1 cells, the mitoribosomal proteins of the small and large subunits 
are both redistributed towards the top of the gradient compared to those in mitochondria from control 
cells, indicating a subunit assembly defect occurred in subject 1 (Figure 4C). Reduced levels of the 
monosome in the cells from subject 1 further indicates that the mitoribosome is destabilized by having 
reduced MRPS34 protein levels, which precludes correct assembly of the small ribosomal subunit and 
consequent association with the large subunit. Overall, these results are consistent with those observed 
in the Mrps34 mutant mouse,18 and confirm that mutation of MRPS34 destabilizes the small ribosomal 
subunit, resulting in impaired mitochondrial translation.  
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Quantitative proteomic analysis of fibroblasts from subject 1 relative to three independent control 
samples was also performed to permit unbiased detection of global cellular protein changes that result 
from the MRPS34 mutation (Table S6). Approximately 4,500 total proteins were quantified across all 
samples by this approach, of which 753 were mitochondrial proteins, including 27 proteins of the 
small mitoribosome subunit and 47 large subunit proteins. The abundance of all detected small 
mitoribosome subunit proteins was significantly decreased in the subject’s cell line compared to 
controls, while none of the proteins from the large mitoribosome subunit were substantially altered 
(Figures 5A and 5B). Figure 5C and the Supplemental Video show the changes in protein abundance 
between subject 1 and controls mapped to the human mitoribosome structure, as we have done 
previously for complex I.42 These representations clearly illustrate the marked decrease in small 
mitoribosomal subunit proteins in subject 1 compared to controls, as well as the relative sparing of the 
large subunit, consistent with destabilization of the small mitoribosomal subunit. Mapping of protein 
levels to the structures of OXPHOS complexes I-IV showed general turnover of the subunits of 
complexes I and IV, and to a lesser extent complex III (Figure 5D), with a trend to increase seen for 
complex II, consistent with reduced translation of mtDNA-encoded mRNAs. As a group, complex I 
and complex IV protein subunits were significantly decreased in subject 1 relative to controls (Figure 
5B and Table S7). Interestingly, the mean subunit level of each OXPHOS complex closely matched 
the residual enzyme activity in the subject’s fibroblasts (Tables S2 and S7). The quantitative 
proteomic data therefore validate destabilization of the small mitoribosomal subunit and the 
consequent impact on mitochondrial translation in subject 1.  
 
Lentiviral-mediated expression of wild-type MRPS34 in fibroblast cells from two affected 
subjects rescues dysfunctional mitochondrial translation and OXPHOS capacity 
To validate the pathogenicity of MRPS34 mutations, we performed complementation studies to 
determine if expression of wild-type MRPS34 in subject cells rescued the mitochondrial translation 
defect. Fibroblasts from control, subject 1, and a subject with a homozygous pathogenic mutation in 
MRPS78 were transduced with a lentiviral vector expressing wild-type MRPS34. The levels of 
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complex IV mtDNA-encoded subunit COXII and complex I nuclear-encoded subunit NDUFB8, a 
marker of complex I stability, were examined by immunoblotting. Densitometry analysis confirmed a 
decrease in COXII and NDUFB8 protein levels in subject 1 and in the subject with MRPS7 mutations 
relative to control (Figures 6A - 6C). Lentiviral-mediated expression of wild-type MRPS34 caused a 
significant increase in COXII and NDUFB8 in subject 1, but not in the cell line from the subject with 
MRPS7 mutations (Figures 6A - 6C), confirming that the disorder of mitochondrial translation in 
subject 1 is due specifically to loss of function mutations in MRPS34. Measurement of complex I and 
complex IV activities using enzyme dipstick assays confirmed that lentiviral-mediated expression of 
wild-type MRPS34 significantly increased complex I and complex IV activity in cells from subject 1, 
but not in cells from the subject with MRPS7 mutations (Figures 6D and 6E). Lentiviral-mediated 
expression of MRPS34 in control cells caused a modest decrease in complex IV activity, suggesting a 
potential negative effect of MRPS34 overexpression in cells with a stable small mitoribosomal 
subunit, though not in contradiction with the rescue observed in cells from subject 1. To further 
support MRPS34 mutation pathogenicity, cells from subject 4 with compound heterozygous MRPS34 
mutations that had been transduced with lentiviral particles expressing wild-type MRPS34 showed 
increased levels of small mitoribosomal subunit proteins MRPS5 and MRPS18B relative to cells 
transduced with red fluorescent protein (Figure 6F). These results provide further evidence that wild-
type MRPS34 rescue stabilized the small mitoribosomal subunit. Collectively, these data establish that 
recessive mutations in MRPS34 cause Leigh syndrome. 
 
Discussion 
We describe six patients from four unrelated families in whom autosomal recessive missense, 
nonsense, or splice site mutations in MRPS34 caused instability of the small mitoribosomal subunit, 
impaired mitochondrial translation, and defective OXPHOS capacity. Subjects with MRPS34 
mutations developed Leigh or Leigh-like syndrome, involving metabolic strokes associated with early 
developmental delay and/or regression. Additional clinical features including microcephaly and 
dysmorphic facies were also observed in several subjects. Our study expands the known genetic 
causes of Leigh (-like) syndrome to now include mutations in a gene that encodes a small 
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mitoribosomal protein.19 While Leigh-like lesions were observed in an adult subject with mutations in 
MRPL44 and a clinical presentation characterized by hypertrophic cardiomyopathy, hemiplegic 
migraine and exercise-induced muscle pain,16 our study broadens the clinical heterogeneity of human 
disorders of the mitoribosome to also include infantile-onset Leigh (-like) syndrome. To date, 
pathogenic mutations in ~10% of all genes encoding mitoribosomal proteins have been described to 
cause disease. This observation is particularly striking in the context that mutations in nearly all of the 
genes encoding mitochondrial aminoacyl-tRNA synthetases, which are also required for 
mitochondrial translation, have been described to cause clinical disease.55,56 This contrast, alongside 
data indicating that a similar proportion of proteins within each group were required for OXPHOS in 
cell models,17 suggests an intriguing discrepancy between these two gene groups in how pathogenic 
mutations have been accumulated and tolerated at a population level.  
 
Although all affected subjects experienced disease onset in early infancy, there was variability in 
disease severity across the cohort. Early death of subjects 1 and 4 occurred within the first year of life, 
while survival into childhood and late adolescence is seen in subjects from families 2 and 3. The 
longer survival in these subjects with the homozygous MRPS34 c.322-10G>A variant could be related 
to this mutation acting as a hypomorphic allele, as we showed that small amounts of wild-type 
transcript are generated in these subjects’ fibroblasts and lymphoblasts. To our knowledge, the 
MRPS34 c.322-10G>A variant has only been identified in individuals of Latino ethnicity, including 
the eight individuals from families 2 and 3 of Puerto Rican descent, and the two heterozygous Latino 
individuals reported in gnomAD, suggesting that this variant may represent a founder mutation. 
Analysis of the available WES data from families 2 and 3 revealed that the MRPS34 c.322-10G>A 
variant lies within a shared haplotype, providing further evidence of a founder effect. The MRPS34 
c.322-10G>A variant should therefore be considered in subjects of Puerto Rican descent with Leigh (-
like) syndrome and OXPHOS defects.  
 
Demonstration of impairments in OXPHOS enzyme activities, mitochondrial translation activity, and 
mitoribosome assembly in affected subjects provided several lines of evidence to support the 
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pathogenicity of biallelic MRPS34 mutations. The rescue of cellular defects associated with impaired 
mitochondrial translation by lentiviral-mediated expression of wild-type MRPS34 transcript in 
fibroblasts from affected subjects further establishes that recessive pathogenic mutations in MRPS34 
cause disease. Quantitative proteomics further confirmed the cellular effects of MRPS34 mutation, 
identifying a general decrease in the level of proteins from the small mitoribosomal subunit and 
OXPHOS complexes I and IV, which were strikingly consistent with enzyme activity results. We 
recently demonstrated the utility of this profiling technique for identifying proteomic signatures of 
expression changes in response to knockout of individual subunits of OXPHOS complex I in gene-
edited cell lines relative to isogenic controls.42 Here, we further demonstrate that it can also serve as 
an effective tool for detecting specific proteomic signatures in fibroblasts from subjects relative to 
fibroblast controls from varied genetic backgrounds. Indeed, in the absence of any prior knowledge of 
disease causation, quantitative proteomic analysis of fibroblasts from subject 1 would have identified 
MRPS34 as the most reduced mitochondrial protein. The decreased amounts of all other small 
ribosomal subunit proteins and subunits from OXPHOS complexes I and IV provide further direct 
support for a defect in stability of the small mitoribosome subunit. Quantitative proteomics therefore 
represents a powerful approach to elucidate the pathogenicity of novel gene mutations, with broad 
utility likely beyond investigation of primary mitochondrial disorders.  
 
The mitoribosomal subunit assembly process in humans is poorly understood.2 Our data from cells of 
a subject with MRPS34 mutations, together with our previous studies on the Mrps34 mutant mouse,18 
show that MRPS34 defects lead to a significant decrease in all small mitoribosomal subunit proteins 
and significantly reduced 12S rRNA levels. These data suggest that MRPS34 plays an important role 
in stabilizing the 12S rRNA and is required for the stability of the small mitoribosomal subunit. The 
relative sparing of the large mitoribosomal subunit in MRPS34 deficient cells is consistent with 
studies examining cell lines from subjects with pathogenic mutations in other small mitoribosomal 
subunit proteins MRPS16 and MRPS22,57 suggesting that the maintenance of large and small 
mitoribosomal subunit levels are not inextricably linked in humans. While the identification of 
affected subjects with pathogenic mutations in mitoribosomal subunit proteins enables key insight 
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into mitoribosome stability, more comprehensive studies are required to enable an intimate 
understanding of mitochondrial ribosomes and protein synthesis. 
 
Although complexes I, III, IV and V all contain mtDNA-encoded subunits, our proteomic data 
suggest that complexes I and IV are more vulnerable than complexes III and V to destabilization 
when there is a defect in mitochondrial translation. We have previously shown that defective 
incorporation of mtDNA-encoded subunits into complexes I and IV can preclude assembly of these 
complexes, resulting in a general destabilization and turnover of unincorporated subunits.40,42 Most of 
the mtDNA-encoded subunits of complexes I and IV that we detected in proteomic analyses of 
MRPS34 deficient fibroblasts appeared to be decreased. This was not the case for the MT-CYB and 
MT-ATP8 subunits of complexes III and IV, suggesting the lesser impact on complexes III and V 
may relate to longer half-lives of these proteins or their stabilization by association with other 
polypeptides within the assembled complex. Further studies are required to determine why different 
OXPHOS complexes are differentially impacted by a defect in mitochondrial translation.   
 
The Mrps34 mutant mouse showed similar defects in mitoribosome assembly and protein synthesis to 
the human disorder,18 but the liver dysfunction that characterized that model was not a clinical feature 
of the six MRPS34 disease subjects reported here. Further analyses of the Mrps34 mutant mice have 
identified kidney dysfunction and smaller brains compared to controls (A.F., unpublished data), 
features seen in common with some of the subjects reported here. However, it remains to be 
determined why liver dysfunction was more prominent in Mrps34 mutant mice. Mutations affecting 
mitochondrial translation machinery have often been associated with liver dysfunction.8,11,58 The 
observed differences in presentation between individual patients and the mouse model may reflect the 
importance of both the location and severity of the mutation (including hypomorphic versus loss of 
function alleles) as well as the genetic background. This consideration is also relevant to the observed 
differences in both onset and progression of clinical disease between the different MRPS34 human 
subjects.  
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In conclusion, our study demonstrates that MRPS34 is required for normal function of the 
mitoribosome and energy-generating mitochondrial OXPHOS system in humans. Autosomal 
recessive splice site, missense, or nonsense mutations that destabilize MRPS34 are causal of clinical 
presentations of Leigh syndrome or a Leigh-like disease.  
 
Accession Numbers 
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Figure Titles and Legends 
Figure 1. Identification of MRPS34 mutations in six subjects from four families. 
(A) Pedigrees and genotype of subjects with MRPS34 variants. ‘-’ denotes a mutant allele.   
(B) Sequencing chromatograms confirming the MRPS34 variants in affected subjects, and the carrier 
status of family members with DNA available.  
(C) Protein sequence alignment of human MRPS34 with its homologs in 9 other vertebrate species 
showing the conservation of the p.Glu13 residue mutated in family 4. Asterisks (*) depict conserved 
amino acids.  
 
Figure 2. Characterisation of MRPS34 in affected subjects with MRPS34 mutations.   
(A) PCR amplicons of MRPS34 exons 1-3 generated from control and subject 1 fibroblast cDNA -/+ 
cycloheximide (CHX). The amplicon detected in subject 1 was smaller than the control amplicon.  
(B) Sequence analysis of the MRPS34 cDNA PCR amplicon detected in subject 1 identified a 24bp 
deletion corresponding to the utilisation of an upstream donor site in exon 1. This splicing mutation 
therefore produces a shortened transcript that results in an in-frame deletion of 8 amino acids, 
p.Val100_Gln107del.  
(C) Schematic diagram depicting the abnormal transcript generated from the c.312+1G>T variant 
(family 1) and two abnormal plus residual wild-type transcript generated from the c.322-10G>A 
variant (families 2 and 3). The distribution of the three transcripts generated from the c.322-10G>A 
variant in S2a fibroblasts (40 clones sequenced) and lymphoblasts (40 clones sequenced) is 
additionally described in the table. The red line indicates the position of the variant. The diagram 
solid black bars represent exons, while the open bars represent untranslated region.   
(D) Protein sequence alignment of human MRPS34 with its homologs in 9 other vertebrate species. 
Asterisks (*) depict conserved amino acids. The 8 amino acids missing from the MRPS34 protein 
produced in subject 1 are highly conserved across the species examined.  
(E) SDS-PAGE western blot of MRPS34 and Complex II 70kDa subunit SDHA (loading control) from 
control (C1 and C2) and subject 1 fibroblasts and liver showed the absence of wildtype MRPS34 
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protein in subject 1. Long exposures revealed faint double banding in subject 1 fibroblast samples 
probed with MRPS34 antibody.  
(F and G) SDS-PAGE western blot of MRPS34 in fibroblasts and lymphoblasts revealed a substantial 
decrease in MRPS34 levels in subjects 2a, 2b and 4 relative to controls (C1 and C2) and to parental 
samples (I-2 and I-1 from family 2). Complex II subunits SDHA and SDHB, VDAC1 and citrate 
synthase represent loading controls. 
 
Figure 3. Evidence of combined OXPHOS deficiency and reduced mitochondrial translation in affected 
subjects with MRPS34 mutations. 
(A, B and C) SDS-PAGE western blot of protein from fibroblasts and lymphoblasts showed reduced 
levels of complex I (CI) and complex IV (CIV) subunits in subjects 1, 2a, 2b and 4 relative to 
controls (C1-C3) and to parental samples (I-2 and I-1 from family 2). Complex II subunits (SDHA 
and SDHB) are indicative of loading.  
(D and E) BN-PAGE western blot of fibroblast protein showed reduced levels of CI and CIV in subjects 
1 and 4 relative to controls (C1 and C2). Complex II (SDHA and SDHB) is indicative of loading.  
(F and G) Protein synthesis in cell lysates was measured by pulse incorporation of 35S-labelled 
methionine and cysteine. Equal amounts of cellular protein were separated by SDS–PAGE and 
visualized by autoradiography. The in vitro pulse labelling of mitochondrial translation products 
revealed decreased levels of mtDNA-encoded subunits in subject 1 and subject 4 relative to controls 
(C1 and C2). The Coomassie stain represents relative loading. 
 (H)  Examination of mitochondrial protein synthesis in control (C) and subject 1 fibroblasts by [35S]-
methionine radiolabelling. Isolated mitochondria were subject to BN-PAGE, following which the 
complexes were visualised by autoradiography. A slower formation of complex IV, was observed in 
subject 1 relative to control. SDHA was used as a loading control. * denotes a non-specific band. 
 
Figure 4. MRPS34 mutations are associated with reduced protein levels of small mitoribosomal subunits 
and destabilization of the mitoribosome.  
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(A and B) SDS-PAGE western blot of protein from fibroblasts showed reduced protein levels of small 
mitoribosomal subunit proteins in subjects 1 (A) and 4 (B) relative to controls (C1 and C2). The 
abundance of large mitoribosomal proteins in subjects 1 and 4 were comparable to controls. 
Complex II subunit SDHA, VDAC1 and GAPDH were used as loading controls. 
(C) A continuous 10-30% sucrose gradient was used to determine the distribution of the small and large 
ribosomal subunit and the monosome in mitochondria isolated from control (C) and subject 1 cells. 
Mitochondrial ribosomal protein markers of the small (MRPS16 and MRPS35) and large (MRPL11 
and MRPL37) ribosomal subunits were detected by immunoblotting with specific antibodies. The 
data are representative of results from three independent biological experiments. The dashed vertical 
lines denote the relevant fractions as indicated.  
 
Figure 5. Quantitative proteomic analysis of fibroblasts from an affected subject with MRPS34 mutations 
identifies a general decrease in small mitoribosomal and OXPHOS subunit proteins. 
(A) Quantitative mass spectrometry of mitochondrial proteins in control and subject 1 fibroblasts 
demonstrates downregulation of small mitoribosome subunits (red dots), as well as OXPHOS 
subunits (blue dots), in subject 1. In contrast, the levels of large mitoribosome subunits (yellow dots) 
in subject 1 are generally unaffected. Proteins examined in this study by SDS-PAGE and observed 
to have reduced levels are indicated by the text labels. The horizontal line within the volcano plot 
represents a significance value of p=0.05, where the levels of proteins represented above the 
horizontal p=0.05 line was regarded as significantly different from control. The two dashed vertical 
lines indicate Log2 changes of >0.5 up- or downregulation relative to controls.  
(B) OXPHOS and mitoribosome protein levels in subject 1 represented as a ratio of the control mean. 
Hashes denote groups that were significantly reduced in subject 1 relative to control (all with p-
value < 0.0001). The middle bar represents the mean value, while the upper and lower bars represent 
the 95% confidence interval of the mean value. Each dot represents a single protein.  
(C) Changes in mitoribosome protein levels between subject 1 relative to controls mapped to the 
structure of the human mitoribosome. As per the inset scale, proteins coloured in blue are decreased, 
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and those coloured in red are increased, in subject 1 relative to controls. Grey indicates no data; 
yellow indicates MRPS34. 
(D) Changes in OXPHOS subunit levels for complexes I-IV mapped to homologous subunits of the 
relevant structure. Colour scale as per (C). 
 
Figure 6. Lentiviral-mediated expression of wild-type MRPS34 rescues the defect in mitochondrial 
translation in cells from affected subjects. 
(A) Fibroblasts from control, subject 1 and a subject with pathogenic MRPS7 variants were transduced 
with wild-type MRPS34 cDNA. Representative SDS-PAGE western blot demonstrates an increase 
in protein levels of CI (NDUFB8) and CIV (COXII) subunits in subject 1 fibroblasts transduced 
with MRPS34 relative to untransduced cells. VDAC1 was used a loading control. 
(B and C) Densitometry analysis revealed that the increase in CI subunit NDUFB8 (B) and CIV subunit 
COXII (C) observed in subject 1 fibroblasts transduced with MRPS34 relative to untransduced cells 
was significant (p = 0.0049 and 0.036 respectively). Results were normalized to VDAC1 and 
presented as the percent of average untransduced control cells. The data represents the mean of three 
independent transfections ± SEM.  
(D and E) Complex I (D) and complex IV (E) activity was measured in fibroblasts from control, subject 1 
and a subject with pathogenic MRPS7 variants that were transduced with wild-type MRPS34 cDNA. 
Complex I and complex IV activity was significantly increased in subject 1 cells transduced with 
wild-type MRPS34 relative to untransduced cells (both p < 0.0001). Complex IV was significantly 
decreased in control cells transduced with wild-type MRPS34 relative to untransduced cells (p = 
0.0004). Results were normalized to citrate synthase and presented as the percent of average 
untransduced control cells. The data represents the mean of three independent transfections ± SEM. 
 (F)  The level of small mitoribosomal subunit proteins MRPS5 and MRPS18B was examined in 
fibroblasts from controls (C1 and C2) and subject 4 transduced with either RFP or wild-type 
MRPS34 by SDS-PAGE western blotting. Fibroblasts from subject 4 that had been transduced with 
wild-type MRPS34 had increased levels of MRPS5 and MRPS18B relative to cells transduced with 
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RFP. β-actin was used as a loading control. The blot shown is representative of 3 independent 
experiments.  
 
Supplemental Video. Change in protein abundance between subject 1 and controls mapped to the 
human mitoribosome structure. The colour scale is as per Figure 5C.   
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Table 1. Biochemical and Clinical Characteristics in Individuals with MRPS34 Variants. 
 
aActivities of OXPHOS enzyme complexes I, II, III, IV (CI, CII, CIII, CIV) were measured in skeletal muscle, liver or skin fibroblasts; for details see Table 
S2. 
bDiagnoses of Leigh syndrome include compatible neuroimaging or postmortem findings. 
 
 
Subject details MRPS34 Variants OXPHOS Enzyme Activitiesa Clinical Summary 
ID Sex Ethnicity cDNA (GenBank: NM_023936.1) 
Protein (GenBank: NP_076425.1) 
Tissue 
 
Deficient Enzymes  
 
Age of 
Onset 
Clinical 
Course 
Clinical Features and Relevant 
Family History 
S1 Male Italian c.[321+1G>T];[321+1G>T], 
p.[Val100_Gln107del];[Val100_Gln107del] 
 
 
Muscle 
Liver 
Fibroblasts 
CI, CIII, CIV 
CI, CIV 
CI, CIV 
4 months Died at 9 
months 
Leigh syndromeb, 
hyperlacticacidemia, microcephaly 
S2a Female Puerto Rican c.[322-10G>A];[322-10G>A], 
p.[Asn108Leufs*12, Asn108Glyfs*50, =]; 
   [Asn108Leufs*12, Asn108Glyfs*50, =] 
 
Muscle  
(19 months) 
Muscle  
(12 years) 
Not deficient 
 
CI, CIII, CIV 
6 months Alive at 
17 years 
Leigh syndromeb, non-verbal, 
microcephaly, horseshoe kidney, mild 
coarsening of facial features 
S2b Female Puerto Rican c.[322-10G>A];[322-10G>A], 
p.[Asn108Leufs*12, Asn108Glyfs*50, =]; 
   [Asn108Leufs*12, Asn108Glyfs*50, =] 
 
Not performed 
6 months Alive at 
14 years 
Leigh-like syndrome, abnormal MRI, 
non-verbal, microcephaly, mild 
coarsening of facial features, sibling 
of S2a 
S3a Female Puerto Rican c.[322-10G>A];[322-10G>A], 
p.[Asn108Leufs*12, Asn108Glyfs*50, =]; 
   [Asn108Leufs*12, Asn108Glyfs*50, =] 
Muscle CI, CII, CIII, CIV 6 months Alive at 
7 years 
Leigh syndromeb, non-verbal, 
suspected sleep apnea, dysmorphic 
facies, precocious adrenarche 
S3b Female Puerto Rican c.[322-10G>A];[322-10G>A], 
p.[Asn108Leufs*12, Asn108Glyfs*50, =]; 
   [Asn108Leufs*12, Asn108Glyfs*50, =] 
 
Not performed 
6 months Alive at 
2 years 
Leigh syndromeb, suspected sleep 
apnea, sibling of S3a 
S4 Male French c.[37G>A];[94C>T],  
p.[Glu13Lys];[Gln32*] 
Muscle 
Fibroblasts 
CIV 
CIV 
~10 days Died at 
8.5 
months 
Leigh syndromeb, transient metabolic 
acidosis, hemodynamic instability 
related to tubulopathy 
